The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma (Review)
- Authors:
- Bingying Zhu
- Shaoqing Ju
- Haidan Chu
- Xianjuan Shen
- Yan Zhang
- Xi Luo
- Hui Cong
-
Affiliations: Laboratory Medicine Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China, Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China - Published online on: March 2, 2018 https://doi.org/10.3892/ol.2018.8157
- Pages: 6094-6106
-
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Rebecca RL, Kimberly KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Durie BGM: Patient Handbook: Multiple Myeloma, Cancer of the Bone Marrow. International Myeloma Foundation; North Hollywood, CA: 2010 | |
|
Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T and Chanan-Khan A: Outcome disparities in multiple myeloma: A SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 158:91–98. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rollig C, Knop S and Bornhauser M: Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Q, Luo F, Ma J and Yu X: Bone metastasis-related MicroRNAs: New targets for treatment. Curr Cancer Drug Targets. 15:716–725. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rossi M, Tagliaferri P and Tassone P: MicroRNAs in multiple myeloma and related bone disease. Ann Transl Med. 3:3342015.PubMed/NCBI | |
|
Rocci A, Hofmeister CC and Pichiorri F: The potential of miRNAs as biomarkers for multiple myeloma. Expert Rev Mol Diagn. 14:947–959. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bi CL and Chng WJ: miRNA deregulation in multiple myeloma. Chin Med J (Engl). 124:3164–3169. 2011.PubMed/NCBI | |
|
Ghobrial IM: Myeloma as a model for the process of metastasis: Implications for therapy. Blood. 120:20–30. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cottini F and Anderson K: Novel therapeutic targets in multiple myeloma. Clin Adv Hematol Oncol. 13:236–248. 2015.PubMed/NCBI | |
|
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, et al: Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study. Leukemia. 31:2443–2448. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmad N, Haider S, Jagannathan S, Anaissie E and Driscoll JJ: MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia. 28:732–738. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, et al: Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 99:511–518. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Hao M, Feng X, Zang M, Qin Y, Yi S, Li Z, Xu Y, Zhou L, Sui W, et al: Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leuk Res. 39:793–799. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shukla GC, Singh J and Barik S: MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI | |
|
Zhang Q, Yan W, Bai Y, Xu H, Fu C, Zheng W, Zhu Y and Ma J: Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo. Oncol Rep. 33:448–456. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Pan J, Mao S and Jin J: IL-17/miR-192/IL-17Rs regulatory feedback loop facilitates multiple myeloma progression. PLoS One. 9:e1146472014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Li F, Saha MN, Abdi J, Qiu L and Chang H: miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res. 21:2399–2411. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rossi M, Amodio N, Di Martino MT, Tagliaferri P, Tassone P and Cho WC: MicroRNA and multiple myeloma: From laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol. 15:459–467. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Di Martino MT, Amodio N, Tassone P and Tagliaferri P: Functional analysis of microRNA in multiple myeloma. Methods Mol Biol. 1375:181–194. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Raimondi L, De Luca A, Morelli E, Giavaresi G, Tagliaferri P, Tassone P and Amodio N: MicroRNAs: Novel crossroads between myeloma cells and the bone marrow microenvironment. Biomed Res Int. 2016:65045932016. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, et al: Downregulation of p53-inducible microRNAs 192, 194 and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 18:367–381. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paíno T, Delgado M, Aires A, Ocio EM, García-Sanz R, et al: Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica. 98:640–648. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Wang LQ, Wong KY, Li ZY and Chim CS: Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma. J Clin Pathol. 68:557–561. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cipolla GA, Park JK, de Oliveira LA, Lobo-Alves SC, de Almeida RC, Farias TD, Lemos Dde S, Malheiros D, Lavker RM and Petzl-Erler ML: A 3′UTR polymorphism marks differential KLRG1 mRNA levels through disruption of a miR-584-5p binding site and associates with pemphigus foliaceus susceptibility. Biochim Biophys Acta. 1859:1306–1313. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao JJ and Carrasco RD: Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: Implications for multiple myeloma therapy. Cancer Res. 74:5351–5358. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Löffler D, Koczan D, Thiesen HJ, Burger R, Gramatzki M and Horn F: Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood. 103:242–251. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Leotta M, Biamonte L, Raimondi L, Ronchetti D, Di Martino MT, Botta C, Leone E, Pitari MR, Neri A, Giordano A, et al: A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol. 229:2106–2116. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shen X, Guo Y, Yu J, Qi J, Shi W, Wu X, Ni H and Ju S: miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor. Clin Exp Med. 16:307–316. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, et al: High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA. 107:7904–7909. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hao M, Zang M, Zhao L, Deng S, Xu Y, Qi F, An G, Qin Y, Sui W, Li F, et al: Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget. 7:19589–19600. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et al: MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Unno K, Zhou Y, Zimmerman T, Platanias LC and Wickrema A: Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma. 50:1865–1871. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, et al: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 113:6669–6680. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, et al: MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct. 6:232011. View Article : Google Scholar : PubMed/NCBI | |
|
Yyusnita, Norsiah, Zakiah I, Chang KM, Purushotaman VS, Zubaidah Z and Jamal R: MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray. Malays J Pathol. 34:133–143. 2012.PubMed/NCBI | |
|
Campo S, Allegra A, D'Ascola A, Alonci A, Scuruchi M, Russo S, Avenoso A, Gerace D, Campo GM and Musolino C: MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma. Br J Haematol. 165:801–813. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Corrigan-Cummins M, Barber EA, Saleh LM, Zingone A, Ghafoor A, Costello R, Zhang Y, Kurlander RJ, Korde N, et al: Aberrant Levels of miRNAs in Bone marrow microenvironment and peripheral blood of myeloma patients and disease progression. J Mol Diagn. 17:669–678. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, et al: Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 136:1835–1844. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:2015.doi: 10.7554/eLife.05005. View Article : Google Scholar | |
|
Betel D, Koppal A, Agius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11:R902010. View Article : Google Scholar : PubMed/NCBI | |
|
Anders G, Mackowiak SD, Jens M, Maaskola J, Kuntzagk A, Rajewsky N, Landthaler M and Dieterich C: doRiNA: A database of RNA interactions in post-transcriptional regulation. Nucleic Acids Res. 40:D180–D186. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shang J, Yao Y, Fan X, Shangguan L, Li J, Liu H and Zhou Y: miR-29c-3p promotes senescence of human mesenchymal stem cells by targeting CNOT6 through p53-p21 and p16-pRB pathways. Biochim Biophys Acta. 1863:520–532. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gulla A, Di Martino MT, Cantafio Gallo ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, et al: A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells. Clin Cancer Res. 22:1222–1233. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, et al: In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget. 4:242–255. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, Chen M, Wang X, Kang Y, Zhou Y, et al: Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma. Cancer Res. 75:4384–4397. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Galm O, Yoshikawa H, Esteller M, Osieka R and Herman JG: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 101:2784–2788. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, Qiao C, Xu J and Li J: miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett. 309:62–70. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Peng J, Thakur A, Zhang S, Dong Y, Wang X, Yuan R, Zhang K and Guo X: Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma. Tumour Biol. 36:8545–8552. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xu S, Cecilia SG, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K and Van Riet I: Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS One. 8:e797522013. View Article : Google Scholar : PubMed/NCBI | |
|
Liang B, Yin JJ and Zhan XR: MiR-301a promotes cell proliferation by directly targeting TIMP2 in multiple myeloma. Int J Clin Exp Pathol. 8:9168–9174. 2015.PubMed/NCBI | |
|
Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, Gullà A, Foresta U, Pitari MR, Botta C, et al: Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 29:2173–2183. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xu H, Liu C, Zhang Y, Guo X, Liu Z, Luo Z, Chang Y, Liu S, Sun Z and Wang X: Let-7b-5p regulates proliferation and apoptosis in multiple myeloma by targeting IGF1R. Acta Biochim Biophys Sin (Shanghai). 46:965–972. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, et al: DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget. 3:1246–1258. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jagannathan S, Vad N, Vallabhapurapu S, Vallabhapurapu S, Anderson KC and Driscoll JJ: MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia. 29:727–738. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YK, Wang H, Leng Y, Li ZL, Yang YF, Xiao FJ, Li QF, Chen XQ and Wang LS: Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. Biochem Biophys Res Commun. 414:233–239. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, et al: miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 12:3650–3662. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gullà AM, Pitari MR, Conforti F, Rossi M, et al: miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 3:e4362012. View Article : Google Scholar : PubMed/NCBI | |
|
Cosco D, Cilurzo F, Maiuolo J, Federico C, Di Martino MT, Cristiano MC, Tassone P, Fresta M and Paolino D: Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Sci Rep. 5:175792015. View Article : Google Scholar : PubMed/NCBI | |
|
Di Martino MT, Campani V, Misso G, Cantafio Gallo ME, Gullà A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, et al: In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One. 9:e900052014. View Article : Google Scholar : PubMed/NCBI | |
|
Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, et al: Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence. Clin Cancer Res. 18:6260–6270. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shen X, Guo Y, Qi J, Shi W, Wu X, Ni H and Ju S: Study on the association between miRNA-202 expression and drug sensitivity in multiple myeloma cells. Pathol Oncol Res. 22:531–539. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gatt ME, Zhao JJ, Ebert MS, Zhang Y, Chu Z, Mani M, Gazit R, Carrasco DE, Dutta-Simmons J, Adamia S, et al: MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood. 2010.doi: 10.1182/blood-2009-11-253294. View Article : Google Scholar : PubMed/NCBI | |
|
Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, Zhang L and Hu Y: miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis. 34:426–435. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D and Anderson KC: Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 120:3958–3967. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Min DJ, Ezponda T, Kim MK, Will CM, Martinez-Garcia E, Popovic R, Basrur V, Elenitoba-Johnson KS and Licht JD: MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia. 27:686–694. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tessel MA, Benham AL, Krett NL, Rosen ST and Gunaratne PH: Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer. 2:182–189. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oeztuerk-Winder F, Guinot A, Ochalek A and Ventura JJ: Regulation of human lung alveolar multipotent cells by a novel p38a MAPK/miR-17-92 axis. EMBO J. 31:3431–3441. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, et al: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 132:875–886. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 19:2548–2556. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Fermiñán E, Martín-Jiménez P, Chillón C, Risueño A, et al: Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 24:629–637. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mraz M, Pospisilova S, Malinova K, Slapak I and Mayer J: MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma. 50:506–509. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, et al: Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 15:1364–1375. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, et al: miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 228:1506–1515. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Wu S, Qu X, Zhao M, Xu J, Jianyong L and Lijuan C: Down-regulation of microRNA-29c is associated with renal failure in multiple myeloma. Leuk Lymphoma. 55:226–228. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Munker R, Liu CG, Taccioli C, Alder H and Heerema N: MicroRNA profiles of drug-resistant myeloma cell lines. Acta Haematol. 123:201–204. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Liu S and Wang Y: MicroRNA-21 and multiple myeloma: Small molecule and big function. Med Oncol. 31:942014. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng P, Guo H, Li G, Han S, Luo F and Liu Y: PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling. Biochem Biophys Res Commun. 458:328–333. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Li C, Ju S, Wang Y, Wang H and Zhong R: Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma. 52:1991–1998. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jones CI, Zabolotskaya MV, King AJ, Stewart HJ, Horne GA, Chevassut TJ and Newbury SF: Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 107:1987–1996. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O and Hajek R: Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma. 54:189–191. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Qu X, Zhao M, Wu S, Yu W, Xu J, Xu J, Li J and Chen L: Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol. 31:2192014. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, Sui W, Hao M and Qiu L: MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget. 6:38270–38282. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D and Kuchenbauer F: Circulating microRNAs in hematological diseases: Principles, challenges and perspectives. Blood. 121:4977–4984. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Liang H, Zhang J, Zen K and Zhang CY: Secreted microRNAs: A new form of intercellular communication. Trends Cell Biol. 22:125–132. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Seckinger A, Meißner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, et al: miRNAs in multiple myeloma-a survival relevant complex regulator of gene expression. Oncotarget. 6:39165–39183. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B and Shaughnessy J Jr: Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood. 106:296–303. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Huang JJ, Yu J, Li JY, Liu YT and Zhong RQ: Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol. 29:2402–2408. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, et al: Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 28:1922–1926. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, et al: Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol. 162:348–359. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Navarro A, Diaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, Magnano L, Rosiñol L, Monzó M, Bladé J and de Larrea Fernández C: A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget. 6:1874–1883. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Pan L, Xiang B, Zhu H, Wu Y, Chen M, Guan P, Zou X, Valencia CA, Dong B, et al: Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget. 7:30876–30891. 2016.PubMed/NCBI | |
|
Yang WC and Lin SF: Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015:3414302015. View Article : Google Scholar : PubMed/NCBI | |
|
Cantafio Gallo ME, Nielsen BS, Mignogna C, Arbitrio M, Botta C, Frandsen NM, Rolfo C, Tagliaferri P, Tassone P and Di Martino MTL: Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates. Mol Ther Nucleic Acids. 5:e3362016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res. 74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guo J, McKenna SL, O'Dwyer ME, Cahill MR and O'Driscoll CM: RNA interference for multiple myeloma therapy: Targeting signal transduction pathways. Expert Opin Ther Targets. 20:107–121. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Palagani A, de Beeck KO, Naulaerts S, Diddens J, Chirumamilla Sekhar C, Van Camp G, Laukens K, Heyninck K, Gerlo S, Mestdagh P, et al: Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells. PLoS One. 9:e1138422014. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Zhang Y, Liu Y, Dai X, Li W, Cai X, Yin Y, Wang Q, Xue Y, Wang C, et al: Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J Biol Chem. 288:23586–23596. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lambert JM, Moshfegh A, Hainaut P, Wiman KG and Bykov VJ: Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. 29:1329–1338. 2010. | |
|
Saha MN, Abdi J, Yang Y and Chang H: miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget. 7:7149–7160. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, Kuglik P, Almasi M, Penka M, Krejci M, et al: Circulating serum MicroRNA-130a as a novel putative marker of extramedullary myeloma. PLoS One. 10:e01372942015. View Article : Google Scholar : PubMed/NCBI |
